1
|
Pitter JG, Mihajlović J, Nagy D, van der Schans J, Vokó Z, Kaló Z. Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults. Vaccine 2025; 56:127184. [PMID: 40318354 DOI: 10.1016/j.vaccine.2025.127184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Revised: 04/23/2025] [Accepted: 04/23/2025] [Indexed: 05/07/2025]
Abstract
Several Central and Eastern European (CEE) countries have low seasonal influenza vaccination coverage of older adults coupled with severe underreporting of influenza-related deaths. Our objective was to project influenza mortality estimates for older adults in six CEE countries, building on high-quality mortality data from an EU-15 country with similar climate, population density, and seasonal influenza vaccination coverage. In addition, we aimed to compare the implications of the reported and projected influenza burden estimates on the economic value of extended influenza vaccination for older adults in an exemplary CEE country, Serbia. Multivariate regression modelling was used to adjust for differences in population health status between countries. Economic implication of underreporting influenza burden was investigated by using the VITALO decision analytic model. Locally reported and projected mortality rates were similar in Czech Republic and Slovenia, whereas projected mortality rates far exceeded locally reported influenza mortality rates in Poland, Hungary, Serbia, and Romania. Based on locally reported mortality rates in Serbia, increasing seasonal influenza vaccination coverage in the 65+ population to average coverage in the EU-27 would prevent 2.86 deaths and would generate 16.52 QALYs at the incremental cost of 2,847,994 EUR annually, which translates to 172,378 EUR/QALY incremental cost-effectiveness ratio (ICER). However, adopting Austrian influenza mortality rates adjusted to higher frailty prevalence in Serbia, increased vaccination coverage would prevent 28.96 deaths and generate 132.77 QALYs at the incremental cost of 2,803,675 EUR annually with an 21,116 EUR/QALY ICER, below Serbian willingness to pay threshold. Accordingly, extension of seasonal influenza vaccination in older adults would be a cost-effective public health intervention in Serbia. Underreporting of adult influenza mortality rates prevent policymakers from understanding the true economic value of influenza vaccination. Our approach is applicable in further countries with low reported influenza mortality rates.
Collapse
Affiliation(s)
- János G Pitter
- Syreon Research Institute, 65A Mexikoi Street, Budapest, Hungary; Division of Pharmacoeconomics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - Jovan Mihajlović
- Mihajlović Health Analytics, 54 Omladinskih radnih akcija, Novi Sad, Serbia; Department of Pharmacotherapy, Pharmacoepidemiology & Pharmacoeconomics, University of Groningen, Groningen, The Netherlands; Medical Faculty, University of Novi Sad, Serbia
| | - Dávid Nagy
- Syreon Research Institute, 65A Mexikoi Street, Budapest, Hungary; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary; Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary.
| | - Jurjen van der Schans
- Department of Health Sciences, Global Health Unit, University Medical Center Groningen, The Netherlands
| | - Zoltán Vokó
- Syreon Research Institute, 65A Mexikoi Street, Budapest, Hungary; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary; Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary
| | - Zoltán Kaló
- Syreon Research Institute, 65A Mexikoi Street, Budapest, Hungary; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary; Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary
| |
Collapse
|
2
|
Puggina A, Dovizio M, Domnich A, Marijam A, Veronesi C, Rizzo C, Vicentini M, Degli Esposti L, Calabrò GE, Fonseca MJ. Healthcare Resource Utilization and Economic Outcomes of RSV-Hospitalized Patients Aged ≥ 60 Years: A Retrospective Cohort Study. Diseases 2025; 13:68. [PMID: 40136607 PMCID: PMC11941357 DOI: 10.3390/diseases13030068] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2024] [Revised: 02/07/2025] [Accepted: 02/17/2025] [Indexed: 03/27/2025] Open
Abstract
Background/Objectives The economic impact of respiratory syncytial virus (RSV) in Italy is not well defined. This analysis assessed the economic outcomes of RSV-hospitalized patients aged ≥ 60 years in Italy. METHODS Healthcare resource utilization and direct healthcare costs during the first RSV hospitalization and 12-month follow-up were collected from Italian administrative databases. A propensity-score-matched (PSM) analysis was performed between patients hospitalized for RSV and those hospitalized for any cause (without an RSV diagnosis). RESULTS Among 201 patients, an average of 1.95 hospitalizations, 19.38 prescriptions, and 7.11 outpatient services were reported during the first RSV hospitalization and the following 12 months. The mean direct healthcare costs were EUR 11,599 (related to hospitalization [79%], prescriptions [16%], and outpatient services [5%]). Following PSM analyses, direct healthcare costs were 15% higher for RSV-hospitalized patients versus those hospitalized for any cause (EUR 9369 versus EUR 8173; p < 0.05), driven by differences in hospitalizations (EUR 7477 versus EUR 6327; p < 0.05) and intensive care unit admissions (EUR 818 versus EUR 178; p = 0.001). CONCLUSIONS Despite a limited sample size, this study reports a substantial economic burden associated with RSV-hospitalized patients aged ≥ 60 years in Italy. The results provide important evidence to inform preventative RSV strategies to reduce the economic burden on the Italian National Health Service.
Collapse
Affiliation(s)
| | - Melania Dovizio
- CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy
| | - Alexander Domnich
- Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy
| | | | - Chiara Veronesi
- CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy
| | - Caterina Rizzo
- Department of Translational Research and New Technologies in Medicine, Surgery University of Pisa, 56126 Pisa, Italy
| | | | - Luca Degli Esposti
- CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy
| | - Giovanna Elisa Calabrò
- VIHTALI (Value in Health Technology and Academy for Leadership & Innovation), Spin-Off of Università Cattolica del Sacro Cuore, 00168 Rome, Italy
- Department of Human Sciences, Society and Health, University of Cassino and Southern Lazio, 03043 Cassino, Italy
| | | |
Collapse
|